RRoche will partner with Dicerna to develop and commercialize the Phase I chronic hepatitis B virus (HBV) candidate DCR-HBVS, as well as discover and develop additional HBV treatments, through a collaboration that could generate more than $1.67 billion for Dicerna. [KATERYNA KON/SCIENCE PHOTO LIBRARY / Getty Images]
Roche will partner with Dicerna to develop and commercialize its lead product, the Phase I chronic hepatitis B virus (HBV) candidate DCR-HBVS, as well as discover and develop additional HBV treatments, through a collaboration that could generate more than $1.67 billion for Dicerna . . .
![New research suggest ketogenic diets may cause an increased risk of Type 2 diabetes in the early stage of the diet. [United States Air Force]](https://www.genengnews.com/wp-content/uploads/2018/08/Aug9_2018_KirtlandAirForceBase_KetogenicDiet_SalmonButterOliveOilCoconutSteak1801911782-80x60.jpg "Ketogenic Diet Alters Gut Microbiome Leading to Reduced Levels of Proinflammatory T Cells")
